The DOI matches its Crossref record; 291 of the 291 references it cites were found in a registry or an index.
Molecular targeting therapies for neuroblastoma: Progress and challenges
Open accessAbstract
There is an urgent need to identify novel therapies for childhood cancers. Neuroblastoma is the most common pediatric solid tumor, and accounts for ~15% of childhood cancer‐related mortality. Neuroblastomas exhibit genetic, morphological and clinical heterogeneity, which limits the efficacy of existing treatment modalities. Gaining detailed knowledge of the molecular signatures and genetic variations involved in the pathogenesis of neuroblastoma is necessary to develop safer and more effective treatments for this devastating disease. Recent studies with advanced high‐throughput “omics” techniques have revealed numerous genetic/genomic alterations and dysfunctional pathways that drive the onset, growth, progression, and resistance of neuroblastoma to therapy. A variety of molecular signatures are being evaluated to better understand the disease, with many of them being used as targets to develop new treatments for neuroblastoma patients. In this review, we have summarized the contemporary understanding of the molecular pathways and genetic aberrations, such as those in MYCN, BIRC5, PHOX2B, and LIN28B, involved in the pathogenesis of neuroblastoma, and provide a comprehensive overview of the molecular targeted therapies under preclinical and clinical investigations, particularly those targeting ALK signaling, MDM2, PI3K/Akt/mTOR and RAS‐MAPK pathways, as well as epigenetic regulators. We also give insights on the use of combination therapies involving novel agents that target various pathways. Further, we discuss the future directions that would help identify novel targets and therapeutics and improve the currently available therapies, enhancing the treatment outcomes and survival of patients with neuroblastoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Items 201–291 of 291
Wu, T., Wu, X., Wang, H., & Chen, L. (2019) · 癌症:英文版 · doi:10.1186/s40880-019-0365-9 · Cited by 67
Neuroblastoma: oncogenic mechanisms and therapeutic exploitation of necroptosis
Nicolai, S., Pieraccioli, M., Peschiaroli, A., Melino, G., & Raschellà, G. (2015) · Cell Death and Disease · doi:10.1038/cddis.2015.354 · Cited by 66
Role and toxicity of radiation therapy in neuroblastoma patients: A literature review
Zhao, Q., Liu, Y., Zhang, Y., Meng, L., Wei, J., Wang, B., Wang, H., Xin, Y., Dong, L., & Jiang, X. M. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.102924 · Cited by 65
Lozier, A., Rich, M. E., Grawe, A. P., Peck, A. S., Zhao, P., Chang, A., Bond, J. P., & Sholler, G. L. S. (2014) · Oncotarget · doi:10.18632/oncotarget.2768 · Cited by 64
Duijkers, F. A. M., Gaal, J., Meijerink, J. P. P., Admiraal, P. C., Pieters, R., de Krijger, R. R., & van Noesel, M. M. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2011.12.003 · Cited by 64
Novel therapeutic strategies targeting telomere maintenance mechanisms in high-risk neuroblastoma
George, S. L., Parmar, V. S., Lorenzi, F., Marshall, L. V., Jamin, Y., Poon, E., Angelini, P., & Chesler, L. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01582-2 · Cited by 64
Gestblom, C., Grynfeld, A., Øra, I., Örtoft, E., Larsson, C., Axelson, H., Sandstedt, B., Cserjesi, P., Olson, E. N., & Påhlman, S. (1999) · PubMed · Cited by 63
Burmakin, M., Shi, Y., Hedström, E., Kogner, P., & Selivanova, G. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2211 · Cited by 63
Bate-Eya, L. T., den Hartog, I. J. M., van der Ploeg, I., Schild, L. G., Köster, J., Santo, E. E., Westerhout, E. M., Versteeg, R., Caron, H. N., Molenaar, J. J., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8547 · Cited by 63
Targeting of epigenetic regulators in neuroblastoma
Jubierre, L., Jiménez, C., Rovira, E., Soriano, A., Sábado, C., Gros, L., Llort, A., Hladun, R., Roma, J. M., de Toledo, J. S., et al. (2018) · Experimental & Molecular Medicine · doi:10.1038/s12276-018-0077-2 · Cited by 62
The Role of Surgery in High-risk Neuroblastoma
Ryan, A. L., Akinkuotu, A. C., Pierro, A., Morgenstern, D. A., & Irwin, M. S. (2019) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0000000000001607 · Cited by 61
DNA demethylation increases sensitivity of neuroblastoma cells to chemotherapeutic drugs
Charlet, J., Schnekenburger, M., Brown, K. W., & Diederich, M. F. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.01.009 · Cited by 60
Aberrant activation of ALK kinase by a novel truncated form ALK protein in neuroblastoma
Okubo, J., Takita, J., Chen, Y., Oki, K., Nishimura, R., Kato, M., Sanada, M., Hiwatari, M., Hayashi, Y., Igarashi, T., et al. (2012) · Oncogene · doi:10.1038/onc.2011.616 · Cited by 60
Advances in emerging drugs for the treatment of neuroblastoma
Berlanga, P., Cañete, A., & Castel, V. (2017) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2017.1294159 · Cited by 60
Modak, S. I., Kushner, B. H., Basu, E. M., Roberts, S. S., & Cheung, N. V. (2017) · Pediatric Blood & Cancer · doi:10.1002/pbc.26448 · Cited by 58
Kushner, B. H., Kramer, K., Modak, S. I., & Cheung, N. V. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.3317 · Cited by 57
Eleveld, T. F., Schild, L. G., Köster, J., Zwijnenburg, D. A., Alles, L. K., Ebus, M. E., Volckmann, R., Tijtgat, G. A., Sluis, P. V., Versteeg, R., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-1045 · Cited by 57
Preclinical models for neuroblastoma: Advances and challenges
Nolan, J. C., Frawley, T., Tighe, J., Soh, H., Curtin, C. M., & Piskareva, O. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.01.015 · Cited by 57
Bachetti, T., Paolo, D. D., Lascio, S. D., Mirisola, V., Brignole, C., Bellotti, M., Caffa, I., Ferraris, C., Fiore, M., Fornasari, D., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013108 · Cited by 56
Cell death-based treatment of neuroblastoma
Valter, K., Zhivotovsky, B., & Gogvadze, V. G. (2018) · Cell Death and Disease · doi:10.1038/s41419-017-0060-1 · Cited by 56
Haug, B. H., Hald, Ø. H., Utnes, P., Roth, S. A., Løkke, C., Flægstad, T., & Einvik, C. (2015) · PubMed · Cited by 55
Qiu, Y.-Y., Mirkin, B. L., & Dwivedi, R. S. (2005) · Cancer Detection and Prevention · doi:10.1016/j.cdp.2005.05.004 · Cited by 55
Lu, Z., Tian, Y., Salwen, H. R., Chlenski, A., Godley, L. A., Raj, J. U., & Yang, Q. (2013) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e32835ffdbb · Cited by 54
Fransson, S. M., Hansson, M., Ruuth, K., Djos, A., Berbegall, A. P., Javanmardi, N., Abrahamsson, J., Palmer, R. H., Noguera, R., Hallberg, B., et al. (2014) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22223 · Cited by 53
ALK amplification and protein expression predict inferior prognosis in neuroblastomas
Wang, M., Zhou, C., Sun, Q., Cai, R., Li, Y., Wang, D., & Gong, L. (2013) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2013.06.002 · Cited by 52
Kushner, B. H., Cheung, N. V., Modak, S. I., Becher, O. J., Basu, E. M., Roberts, S. S., Kramer, K., & Dunkel, I. J. (2016) · International Journal of Cancer · doi:10.1002/ijc.30440 · Cited by 52
HIF-1α Contributes to Proliferation and Invasiveness of Neuroblastoma Cells via SHH Signaling
Chen, S., Zhang, M., Xing, L., Wang, Y., Xiao, Y., & Wu, Y. (2015) · PLoS ONE · doi:10.1371/journal.pone.0121115 · Cited by 51
HIF-1α activation mediates resistance to anti-angiogenic therapy in neuroblastoma xenografts
Hartwich, J. E., Orr, W. S., Ng, C. Y., Spence, Y., Morton, C. L., & Davidoff, A. M. (2013) · Journal of Pediatric Surgery · doi:10.1016/j.jpedsurg.2012.10.016 · Cited by 51
Yang, Y., Ding, L., Zhou, Q., Li, F., Cao, Y.-H., Sun, J., Zhou, X., & Liu, A. (2020) · Cancer Cell International · doi:10.1186/s12935-019-1072-y · Cited by 51
Antiproliferative and apoptotic effect of LY2090314, a GSK-3 inhibitor, in neuroblastoma in vitro
Kunnimalaiyaan, S., Schwartz, V. K., Jackson, I. A., Gamblin, T. C., & Kunnimalaiyaan, M. (2018) · BMC Cancer · doi:10.1186/s12885-018-4474-7 · Cited by 50
Aveic, S., Pantile, M., Seydel, A., Esposito, M. R., Zanon, C., Li, G., & Tonini, G. P. (2015) · Oncotarget · doi:10.18632/oncotarget.6778 · Cited by 49
Cattelani, S., Defferrari, R., Marsilio, S., Bussolari, R., Candini, O., Corradini, F., Ferrari‐Amorotti, G., Guerzoni, C., Pecorari, L., Menin, C., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4725 · Cited by 48
Delloye‐Bourgeois, C., & Castellani, V. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00052 · Cited by 48
Molecularly Targeted Therapy for Neuroblastoma
Greengard, E. G. (2018) · Children · doi:10.3390/children5100142 · Cited by 47
Homozygous deletion and expression of PTEN and DMBT1 in human primary neuroblastoma and cell lines
Muñoz, J., Lázcoz, P., Inda, M. D. M., Nistal, M., Pestaña, Á., Encío, I., & Castresana, J. S. (2004) · International Journal of Cancer · doi:10.1002/ijc.20055 · Cited by 45
Upfront treatment of high‐risk neuroblastoma with a combination of 131 I‐MIBG and topotecan
Kraal, K. C. J. M., Tytgat, G. A. M., van Eck‐Smit, B. L. F., Kam, B. L. R., Caron, H. N., & van Noesel, M. M. (2015) · Pediatric Blood & Cancer · doi:10.1002/pbc.25580 · Cited by 44
Cheung, I. Y., Kushner, B. H., Modak, S. I., Basu, E. M., Roberts, S. S., & Cheung, N. V. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1358331 · Cited by 44
Monitoring Immune Responses in Neuroblastoma Patients during Therapy
Szanto, C. L., Cornel, A. M., Vijver, S. V., & Nierkens, S. (2020) · Cancers · doi:10.3390/cancers12020519 · Cited by 44
Cavalli, E., Ciurleo, R., Petralia, M. C., Fagone, P., Bella, R., Mangano, K., Nicoletti, F., Bramanti, P., & Basile, M. S. (2020) · Molecules · doi:10.3390/molecules25051194 · Cited by 44
The role of anaplastic lymphoma kinase in pediatric cancers
Takita, J. (2017) · Cancer Science · doi:10.1111/cas.13333 · Cited by 42
Non-High-Risk Neuroblastoma: Classification and Achievements in Therapy
Meany, H. J. (2019) · Children · doi:10.3390/children6010005 · Cited by 41
Peirce, S. K., Findley, H. W., Prince, C. Z., Dasgupta, A., Cooper, T. M., & Durden, D. L. (2010) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-010-1486-7 · Cited by 40
Courtland, J. L., Iyer, R., Li, N., Molteni, V., Loren, J. C., Gordon, W. P., Tuntland, T., Liu, B., & Brodeur, G. M. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2627-1 · Cited by 40
Novel MDM2 inhibitor SAR405838 (MI-773) induces p53-mediated apoptosis in neuroblastoma
Lu, J., Guan, S., Zhao, Y., Yu, Y., Wang, Y., Shi, Y., Mao, X., Yang, K. L., Sun, W., Xu, X. Y., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12634 · Cited by 40
Wnt Signalling Drives Context-Dependent Differentiation or Proliferation in Neuroblastoma
Szemes, M., Greenhough, A., Melegh, Z., Malik, S., Yuksel, A., Catchpoole, D. R., Gallacher, K., Kollareddy, M., Park, J. H., & Malik, K. T. A. (2018) · Neoplasia · doi:10.1016/j.neo.2018.01.009 · Cited by 40
Select Bcl-2 antagonism restores chemotherapy sensitivity in high-risk neuroblastoma
Tanos, R., Karmali, D., Nalluri, S., & Goldsmith, K. C. (2016) · BMC Cancer · doi:10.1186/s12885-016-2129-0 · Cited by 39
Emerging and investigational therapies for neuroblastoma
Applebaum, M. A., Desai, A. V., Bender, J. G., & Cohn, S. L. (2017) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2017.1304212 · Cited by 39
Lau, L. M. S., Hansford, L. M., Cheng, L. S., Hang, M., Baruchel, S., Kaplan, D. R., & Irwin, M. S. (2006) · Oncogene · doi:10.1038/sj.onc.1209981 · Cited by 38
The roles played by the MYCN, Trk, and ALK genes in neuroblastoma and neural development
Higashi, M., Sakai, K., Fumino, S., Aoi, S., Furukawa, T., & Tajiri, T. (2019) · Surgery Today · doi:10.1007/s00595-019-01790-0 · Cited by 38
Sunitinib Suppress Neuroblastoma Growth through Degradation of MYCN and Inhibition of Angiogenesis
Calero, R., Morchon, E., Johnsen, J. I., & Serrano, R. (2014) · PLoS ONE · doi:10.1371/journal.pone.0095628 · Cited by 37
Persson, C. U., von Stedingk, K., Fredlund, E., Bexell, D., Påhlman, S., Wigerup, C., & Mohlin, S. (2020) · Experimental Cell Research · doi:10.1016/j.yexcr.2020.111845 · Cited by 37
Kang, M. H., Reynolds, C. P., Kolb, E. A., Gorlick, R., Carol, H., Lock, R., Keir, S. T., Maris, J. M., Wu, J., Lyalin, D., et al. (2016) · Pediatric Blood & Cancer · doi:10.1002/pbc.26064 · Cited by 36
Dual targeting of MDM2 and BCL2 as a therapeutic strategy in neuroblastoma
Goethem, A. V., Yigit, N., Moreno‐Smith, M., Vasudevan, S. A., Barbieri, E., Speleman, F., Shohet, J. M., Vandesompele, J., & Maerken, T. V. (2017) · Oncotarget · doi:10.18632/oncotarget.18982 · Cited by 36
WNT Signaling in Neuroblastoma
Becker, J., & Wilting, J. (2019) · Cancers · doi:10.3390/cancers11071013 · Cited by 35
Hypoxia in the Initiation and Progression of Neuroblastoma Tumours
Castaño, C. H., Gómez-Muñoz, M. A., Pardal, R., & Vega, F. M. D. L. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms21010039 · Cited by 35
Bellary, A., Villarreal, A., Eslami, R., Undseth, Q. J., Lec, B., Defnet, A. M., Bagrodia, N., Kandel, J. J., Borden, M. A., Shaikh, S., et al. (2020) · Theranostics · doi:10.7150/thno.45903 · Cited by 35
Chen, L., Pastorino, F., Berry, P., Bonner, J. J., Kirk, C., Wood, K. M., Thomas, H. D., Zhao, Y., Daga, A., Veal, G. J., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.32058 · Cited by 33
Mutations in PIK3CAare infrequent in neuroblastoma
Dam, V., Morgan, B. T., Mazánek, P., & Hogarty, M. D. (2006) · BMC Cancer · doi:10.1186/1471-2407-6-177 · Cited by 32
miRNA Regulation of Glutathione Homeostasis in Cancer Initiation, Progression and Therapy Resistance
Marengo, B., Pulliero, A., Izzotti, A., & Domenicotti, C. (2019) · MicroRNA · doi:10.2174/2211536609666191218103220 · Cited by 32
Bortezomib inhibits angiogenesis and reduces tumor burden in a murine model of neuroblastoma
Hamner, J. B., Dickson, P. V., Sims, T. L., Zhou, J., Spence, Y., Ng, C., & Davidoff, A. M. (2007) · Surgery · doi:10.1016/j.surg.2007.04.012 · Cited by 31
Self-citationZins, K., Schäfer, R., Paulus, P., Dobler, S., Fakhari, N., Sioud, M., Aharinejad, S., & Abraham, D. (2016) · Oncotarget · doi:10.18632/oncotarget.10070 · Cited by 31
Levesley, J., Steele, L. P., Brüning‐Richardson, A., Davison, A., Zhou, J., Ding, C., Lawler, S. E., & Short, S. C. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox134 · Cited by 30
Self-citationKushner, B. H., Modak, S. I., Basu, E. M., Roberts, S. S., Kramer, K., & Cheung, N. V. (2013) · Cancer · doi:10.1002/cncr.28137 · Cited by 29
Wang, W., Zhong, Q., Teng, L., Bhatnagar, N., Sharma, B., Zhang, X., Luther, W., Haynes, L. P., Burgoyne, R. D., Vidal, M., et al. (2013) · Oncogene · doi:10.1038/onc.2013.290 · Cited by 29
Self-citationNifurtimox reduces N-Myc expression and aerobic glycolysis in neuroblastoma
Stanchi, K. M. C., Bruchelt, G., Handgretinger, R., & Holzer, U. (2015) · Cancer Biology & Therapy · doi:10.1080/15384047.2015.1070987 · Cited by 29
Ribeiro, D., Klarqvist, M. D. R., Westermark, U., Oliynyk, G., Dzieran, J., Kock, A., Banares, C. S., Hertwig, F., Johnsen, J. I., Fischer, M., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.06.052 · Cited by 29
Anti-tumor effect of AZD8055 against neuroblastoma cells in vitro and in vivo
Xu, D., Toyoda, H., Yuan, X., Qi, L., Chelakkot, V. S., Morimoto, M., Hanaki, R., Kihira, K., Hori, H., Komada, Y., et al. (2018) · Experimental Cell Research · doi:10.1016/j.yexcr.2018.02.032 · Cited by 29
The prognostic roles of and correlation between ALK and MYCN protein expression in neuroblastoma
Chang, H., Lu, M., Yang, Y., Chou, S., Lin, D., Lin, K., Hsu, W., Jeng, Y., & Jou, S. (2019) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2019-206063 · Cited by 29
Bartolucci, S., Mose, R., Longo, A., Mose, R., Estenoz, M., Momparler, R. L., Santoro, B., & Augusti-Tocco, G. (1989) · Cell Differentiation and Development · doi:10.1016/0922-3371(89)90043-9 · Cited by 27
Iyer, R., Varela, C. R., Minturn, J. E., Ho, R., Simpson, A. M., Light, J. E., Evans, A. E., Zhao, H., Thress, K. S., Brown, J. L., et al. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-1879-x · Cited by 27
Shim, J., Staruch, R., Koral, K., Xie, X., Chopra, R., & Laetsch, T. W. (2016) · Pediatric Blood & Cancer · doi:10.1002/pbc.26079 · Cited by 27
Nguyen, R., Sahr, N. A., Sykes, A. D., McCarville, M. B., Federico, S. M., Sooter, A., Cullins, D. L., Rooney, B., Janssen, W. E., Talleur, A. C., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000176 · Cited by 27
Li, Z., Zhang, Y., Tong, Y., Tong, J., & Thiele, C. J. (2015) · Cancer Biology & Therapy · doi:10.1080/15384047.2015.1016659 · Cited by 26
The angiogenic growth factors HGF and VEGF in serum and plasma from neuroblastoma patients.
Sköldenberg, E. G., Larsson, A. O., Jakobson, Å. M., Hedborg, F., Kogner, P., Christofferson, R. H. B., & Azarbayjani, F. (2009) · PubMed · Cited by 26
Brodeur, G. M. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.344 · Cited by 25
Giustiniano, M., Daniele, S., Pelliccia, S., Pietra, V. L., Pietrobono, D., Brancaccio, D., Cosconati, S., Messere, A., Giuntini, S., Cerofolini, L., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00912 · Cited by 25
Autophagy inhibition improves the cytotoxic effects of receptor tyrosine kinase inhibitors
Aveic, S., Pantile, M., Polo, P., Sidarovich, V., Mariano, M. D., Quattrone, A., Longo, L., & Tonini, G. P. (2018) · Cancer Cell International · doi:10.1186/s12935-018-0557-4 · Cited by 25
NCI Image-Guided Drug Delivery Summit
Tandon, P., & Farahani, K. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2629 · Cited by 24
ALK positively regulates MYCN activity through repression of HBP1 expression
Claeys, S., Denecker, G., Durinck, K., Decaesteker, B., Mus, L. M., Loontiens, S., Vanhauwaert, S., Althoff, K., Wigerup, C., Bexell, D., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0595-3 · Cited by 24
Ramaiah, M. J., Pushpavalli, S. N. C. V. L., Lavanya, A., Bhadra, K., Haritha, V., Patel, N., Tamboli, J. R., Kamal, Ä., Bhadra, U., & Pal‐Bhadra, M. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.08.018 · Cited by 23
Ueda, T., Nakata, Y., Yamasaki, N., Oda, H., Sentani, K., Kanai, A., Onishi, N., Ikeda, K., Sera, Y., Honda, Z.-I., et al. (2016) · Oncogene · doi:10.1038/onc.2015.519 · Cited by 23
Mariano, M. D., Stigliani, S., Moretti, S., Parodi, F., Croce, M., Bernardi, C., Pagano, A., Tonini, G. P., Ferrini, S., & Longo, L. (2017) · Oncotarget · doi:10.18632/oncotarget.17033 · Cited by 22
In Vitro Characterization of a Potent p53-MDM2 Inhibitor, RG7112 in Neuroblastoma Cancer Cell Lines
Al‐Ghabkari, A., & Narendran, A. (2019) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2018.2732 · Cited by 22
Phosphoproteomics reveals ALK promote cell progress via RAS/JNK pathway in neuroblastoma
Chen, K., Lv, F., Xu, G., Zhang, M., Wu, Y., & Wu, Z. (2016) · Oncotarget · doi:10.18632/oncotarget.12513 · Cited by 20
PI3King on MYCN to Improve Neuroblastoma Therapeutics
Hogarty, M. D., & Maris, J. M. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.01.018 · Cited by 19
Tesson, M., Vasan, R., Hock, A., Nixon, C., Rae, C. J., Gaze, M. N., & Mairs, R. J. (2018) · Oncotarget · doi:10.18632/oncotarget.25607 · Cited by 18
Subramanian, C., Grogan, P. T., Opipari, V. P., Timmermann, B. N., & Cohen, M. S. (2018) · Oncotarget · doi:10.18632/oncotarget.24429 · Cited by 17
Zanni, E. D., Fornasari, D., Ravazzolo, R., Ceccherini, I., & Bachetti, T. (2015) · Experimental Cell Research · doi:10.1016/j.yexcr.2015.03.025 · Cited by 16
The effect on cell growth by Wnt1 RNAi in human neuroblastoma SH-SY5Y cell line
Zhang, L., Li, K., Lv, Z., Xiao, X., & Zheng, J. (2009) · Pediatric Surgery International · doi:10.1007/s00383-009-2481-0 · Cited by 13
ALK and GSK3: Shared Features of Neuroblastoma and Neural Crest Cells
Malagon, S. G. G., & Liu, K. J. (2018) · Journal of Experimental Neuroscience · doi:10.1177/1179069518792499 · Cited by 11
Radhakrishnan, S. K., Bebb, D. G., & Lees‐Miller, S. P. (2013) · Translational Cancer Research · doi:10.21037/1123 · Cited by 8
Metadata
- Authors
- Zafar, A., Wang, W., Liu, G., Wang, X., Xian, W., McKeon, F., Foster, J., Zhou, J., & Zhang, R.
- Venue
- Medicinal Research Reviews
- Publisher
- Wiley
- Published
- 2020-11-06
- Volume
- 41
- Issue
- 2
- Pages
- 961-1021
- ISSN
- 0198-6325 (ISSN-L)
- 1098-1128
- OpenAlex
- W3095538345
- Cited by
- 380
- References
- 291
- FWCI
- 15.77
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.